A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C.

  • 1 June 1977
    • journal article
    • clinical trial
    • Vol. 27  (4) , 158-61
Abstract
In a phase II trial, prednimustine was often efficient in treating chronic lymphoid leukaemia (CLL) patients and was also active in some patients with lymphosarcoma, melanoma and bronchus carcinoma. Tolerance was generally excellent, the most critical side effect being thrombocytopenia in the case of CLL.

This publication has 0 references indexed in Scilit: